Showing 8521-8530 of 20878 results for "".
Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
https://reachmd.com/programs/cme/beyond-raasi-and-approved-therapies-the-unmet-needs-in-igan/54683/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
https://reachmd.com/programs/cme/translating-guidelines-to-action-in-igan-embracing-a-simultaneous-dual-concordant-approach/54687/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Emerging Evidence: IgAN Disease-Modifying Agents
https://reachmd.com/programs/cme/emerging-evidence-igan-disease-modifying-agents/54684/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Emerging Therapies in IgAN: Who Could Benefit the Most?
https://reachmd.com/programs/cme/emerging-therapies-in-igan-who-could-benefit-the-most/54685/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Mechanism-Based Targeting: Why APRIL Matters in IgAN
https://reachmd.com/programs/cme/mechanism-based-targeting-why-april-matters-in-igan/54681/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
https://reachmd.com/programs/cme/the-4-hit-hypothesis-foundations-of-igan-pathogenesis/51035/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
https://reachmd.com/programs/cme/targeting-lower-proteinuria-levels-shifting-the-goalpost-in-igan/54686/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Early Onset of Response to Zasocitinib (TAK-279), a Highly Selective and Potent TYK2 Inhibitor, Is Correlated With Modulation of TYK2 Signaling and Disease Pathway Biomarkers in Patients With Moderate-to-Severe Plaque Psoriasis
https://reachmd.com/clinical-practice/dermatology/early-onset-of-response-to-zasocitinib-tak-279-a-highly-selective-and-potent-tyk2-inhibitor-is-correlated-with-modulation-of-tyk2-signaling-and-disease-pathway-biomarkers-in-patients-with-moderate-to-severe-plaque-psoriasis/50977/Review phase 2b trial data on zasocitinib in patients with moderate-to-severe plaque psoriasis.Does an IV Hydration Therapy Practice Need a Medical Director?
https://reachmd.com/ma-issues-index/2022-nov-dec/does-an-iv-hydration-therapy-practice-need-a-medical-director/35231/It’s important to understand requirements in your state.Non-Stimulant Options for ADHD Patients
https://reachmd.com/programs/focus-on-neurology-and-psychiatry/non-stimulant-options-for-adhd-patients/4383/Although stimulant medications are often used to treat ADHD patients, there are patients for whom non-stimulants might also be a viable option. What are the advantages to each type of medication? Dr. Richard Rubin, clinical associate professor at the University of Vermont College of Medicine and adj